共 50 条
- [32] Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naive and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA). ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S705 - S705
- [34] Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S780 - S781
- [35] Improvement & Maintenance of Hemoglobin Levels Among Rheumatoid Arthritis, Psoriatic Arthritis&Ankylosing Spondylitis Patients with Anemia of Inflammation After Treatment with Golimumab:3 Year Pooled Analysis ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S487 - S487
- [36] Is there an Association between Skin- and Joint Manifestations in Patients with Psoriatic Arthritis? - Data Analysis of a German non-interventional Study with Adalimumab in active Psoriatic Arthritis ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 130 - 130
- [38] Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis BMC Musculoskeletal Disorders, 18
- [39] THE PERSISTENCE OF GOLIMUMAB IN DAILY CLINICAL PRACTICE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, AND PSORIATIC ARTHRITIS : ANALYSIS OF PROSPECTIVELY COLLECTED DATA IN THE SLOVENIAN NATIONAL ONLINE REGISTRY OF PATIENTS TREATED WITH BIOLOGICS VALUE IN HEALTH, 2016, 19 (03) : A228 - A228